Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEPin: Early Secukinumab vs Narrowband UVB in New-Onset Moderate to Severe Plaque Psoriasis
2015-002423-26Phase 4Terminated
- Sponsor
- Novartis
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of secukinumab in plaque psoriasis (2 arms), sponsored by Novartis. Primary endpoint: PASI 90 response at Week 52. Started Oct 2016; status: terminated.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2015-002423-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002423-26.